Lantus® vs Premix
Effective glycemic control achieved with insulin
- A1C ≤7% was achieved by 49.4% of patients in the Lantus® + OADs
group vs 39.0% of patients in the premix 70/30 group (P=0.0596)
- Target fasting glucose ≤100 mg/dL was achieved by 31.6% of Lantus®
+ OADs patients vs 15.0% of premix 70/30 patients at the end of the study (P=0.0002)
Safety Results
Lantus® vs Analog Premix
Insulin significantly lowered A1C in patients uncontrolled on OADs
- A1C ≤7% was achieved by 66% of patients in the BiAsp 70/30 + OAD(s) group vs
40% of patients in the Lantus® + OAD(s) group (P<0.001)
- At study end, total daily insulin doses in the Lantus® + OAD(s) group
and BiAsp 70/30 + OAD group were 51.3 Units (±26.7 U) and 78.5 Units (±39.5
U), respectively
In the Raskin Study
Insulin added to OADs lowered fasting, preprandial, and postprandial glucose
- Target FPG (80-110 mg/dL) was achieved by 57% of Lantus® + OAD(s)
patients vs 36% of BiAsp 70/30 + OAD(s) patients at the end of the study
Safety Results2
- Use caution in patients with hypoglycemia unawareness and in patients who may be
predisposed to hypoglycemia. The patient's ability to concentrate and react may
be impaired as a result of hypoglycemia. This may present a risk in situations where
these abilities are especially important, such as driving or operating other machinery.
Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)
Contraindications
Lantus® is contraindicated in patients hypersensitive to insulin glargine or
one of its excipients.
Warnings and Precautions
Monitor blood glucose in all patients treated with insulin. Insulin regimens should
be modified cautiously and only under medical supervision. Changes in insulin strength,
manufacturer, type, or method of administration may result in the need for a change
in insulin dose or an adjustment in concomitant oral antidiabetic treatment.
Do not dilute or mix Lantus® with any other insulin or solution. If mixed or
diluted, the solution may become cloudy, and the onset of action/time to peak effect
may be altered in an unpredictable manner. Do not administer Lantus® via an
insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices
and needles must not be shared between patients.
Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®,
and may be life-threatening.
Severe life-threatening, generalized allergy, including anaphylaxis, can occur.
A reduction in the Lantus® dose may be required in patients with renal or hepatic
impairment.
Drug Interactions
Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and
close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients
taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).
Adverse Reactions
Other adverse reactions commonly associated with Lantus® are injection site
reaction, lipodystrophy, pruritus, and rash.
Important Safety Information for Lantus®
SoloSTAR®
Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure
an accurate dose each time, patients should follow all steps in the Instruction
Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin,
which may affect their blood glucose.
Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)
Lantus® is a long-acting insulin analog indicated to improve glycemic control
in adults and children (6 years and older) with type 1 diabetes mellitus and in
adults with type 2 diabetes mellitus. Lantus® should be administered once a
day at the same time every day.
Important Limitations of Use: Lantus® is not recommended for the treatment of
diabetic ketoacidosis. Use intravenous short-acting insulin instead.
Lantus® SoloSTAR® is a disposable prefilled insulin pen.
Please click
here for Full Prescribing Information for Lantus®.
References:
- Janka HU, Plewe G, Riddle MC, et al. Diabetes Care. 2005;28(2):254-259.
- Raskin P, Allen E, Hollander P, et al; INITIATE Study Group. Diabetes
Indications and Usage for Lantus® (insulin glargine
[rDNA origin] injection)
Lantus® is a long-acting insulin analog indicated to improve glycemic control
in adults and children (6 years and older) with type 1 diabetes mellitus and in
adults with type 2 diabetes mellitus. Lantus® should be administered once a
day at the same time every day.
Important Limitations of Use: Lantus® is not recommended for the treatment of
diabetic ketoacidosis. Use intravenous short-acting insulin instead.
Important Safety Information for Lantus® (insulin
glargine [rDNA origin] injection)
Contraindications
Lantus® is contraindicated in patients hypersensitive to insulin glargine or
one of its excipients.
Warnings and Precautions
Monitor blood glucose in all patients treated with insulin. Insulin regimens should
be modified cautiously and only under medical supervision. Changes in insulin strength,
manufacturer, type, or method of administration may result in the need for a change
in insulin dose or an adjustment in concomitant oral antidiabetic treatment.
Important Safety Information for Lantus® SoloSTAR®
Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure
an accurate dose each time, patients should follow all steps in the Instruction
Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin,
which may affect their blood glucose.
Click here for additional Important Safety Information.